Opaleye Management Inc. lessened its holdings in Chimerix Inc (NASDAQ:CMRX) by 57.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 600,000 shares of the biopharmaceutical company’s stock after selling 803,000 shares during the quarter. Chimerix makes up about 0.9% of Opaleye Management Inc.’s holdings, making the stock its 26th largest position. Opaleye Management Inc. owned 1.27% of Chimerix worth $2,778,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its holdings in Chimerix by 112.3% in the third quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock valued at $1,055,000 after buying an additional 106,267 shares during the last quarter. Citadel Advisors LLC increased its holdings in Chimerix by 131.8% in the third quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock valued at $869,000 after buying an additional 94,108 shares during the last quarter. Nationwide Fund Advisors increased its holdings in Chimerix by 70.3% in the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 24,994 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Chimerix in the third quarter valued at $428,000. Finally, Acadian Asset Management LLC purchased a new position in Chimerix in the fourth quarter valued at $280,000. 72.69% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently commented on CMRX. JPMorgan Chase & Co. lowered Chimerix from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. HC Wainwright began coverage on Chimerix in a report on Friday, February 2nd. They issued a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research lowered Chimerix from a “hold” rating to a “sell” rating in a report on Monday, January 22nd. Finally, ValuEngine lowered Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Chimerix has a consensus rating of “Hold” and an average target price of $7.06.
Chimerix Inc (NASDAQ:CMRX) opened at $5.02 on Tuesday. Chimerix Inc has a twelve month low of $4.17 and a twelve month high of $6.64.
COPYRIGHT VIOLATION NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://weekherald.com/2018/02/20/chimerix-inc-cmrx-position-reduced-by-opaleye-management-inc.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.